patient_id stringlengths 20 22 | cancer_type stringclasses 1
value | histology stringclasses 2
values | stage_at_diagnosis stringclasses 2
values | molecular_profile dict | baseline_clinical dict | disease_burden_at_dx dict | treatment_course dict | survival_outcomes dict | longitudinal_labs listlengths 3 3 |
|---|---|---|---|---|---|---|---|---|---|
ANODE_SYNTH_2025_201 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 83,
"sex": "female",
"bmi": 37.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.6,
"metastatic_sites": [
"bone",
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-10-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -36,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 22.7
},
"second_line_... | {
"overall_survival_months": 39,
"censored": false
} | [
{
"date": "2022-08-14T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 9.1,
"platelets_k_uL": 166,
"creatinine_mg_dL": 0.95,
"alt_U_L": 37
},
{
"date": "2023-04-20T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.7,
"platelets_k_uL": 339,
"creatinine_mg_dL": 0.93,
"... |
ANODE_SYNTH_2025_202 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 74,
"sex": "male",
"bmi": 21.9,
"smoking_pack_years": 23,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.5,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-05-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 21.32
... | {
"overall_survival_months": 34.1,
"censored": true
} | [
{
"date": "2021-04-21T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 6,
"platelets_k_uL": 157,
"creatinine_mg_dL": 1,
"alt_U_L": 42
},
{
"date": "2021-11-18T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 6.1,
"platelets_k_uL": 135,
"creatinine_mg_dL": 1.49,
"alt... |
ANODE_SYNTH_2025_203 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 79,
"sex": "male",
"bmi": 35.2,
"smoking_pack_years": 17,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"bone",
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-10-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 25
},
... | {
"overall_survival_months": 45,
"censored": true
} | [
{
"date": "2023-08-17T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 9.2,
"platelets_k_uL": 184,
"creatinine_mg_dL": 0.89,
"alt_U_L": 77
},
{
"date": "2024-04-09T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 6.6,
"platelets_k_uL": 137,
"creatinine_mg_dL": 1.07,
... |
ANODE_SYNTH_2025_204 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 13.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28
} | {
"age": 63,
"sex": "female",
"bmi": 36.5,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-08-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -52,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 17.41
},
"second_line... | {
"overall_survival_months": 29.1,
"censored": false
} | [
{
"date": "2021-06-22T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 7,
"platelets_k_uL": 370,
"creatinine_mg_dL": 1.23,
"alt_U_L": 41
},
{
"date": "2022-02-10T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 8.8,
"platelets_k_uL": 299,
"creatinine_mg_dL": 0.72,
"al... |
ANODE_SYNTH_2025_205 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 88,
"sex": "female",
"bmi": 30.3,
"smoking_pack_years": 71,
"ecog_performance_status": 0,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.9,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-03-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -38
},
"pfs_months": 8.94
},
"second_line_t... | {
"overall_survival_months": 14.9,
"censored": false
} | [
{
"date": "2022-02-17T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 7.1,
"platelets_k_uL": 180,
"creatinine_mg_dL": 1.27,
"alt_U_L": 52
},
{
"date": "2022-09-06T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 4.8,
"platelets_k_uL": 309,
"creatinine_mg_dL": 1.13,
... |
ANODE_SYNTH_2025_206 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 26
} | {
"age": 71,
"sex": "female",
"bmi": 25.5,
"smoking_pack_years": 32,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-03-12T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 13.93
},
"second_line_th... | {
"overall_survival_months": 27.5,
"censored": false
} | [
{
"date": "2020-01-23T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 4.7,
"platelets_k_uL": 331,
"creatinine_mg_dL": 1.01,
"alt_U_L": 61
},
{
"date": "2020-09-08T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 8,
"platelets_k_uL": 254,
"creatinine_mg_dL": 1.01,
"... |
ANODE_SYNTH_2025_207 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 55,
"sex": "male",
"bmi": 25.4,
"smoking_pack_years": 44,
"ecog_performance_status": 0,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"bone",
"pleura",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-10-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -47
},
"pfs_months": 17.28
... | {
"overall_survival_months": 33.5,
"censored": false
} | [
{
"date": "2020-08-18T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 7,
"platelets_k_uL": 417,
"creatinine_mg_dL": 1.02,
"alt_U_L": 32
},
{
"date": "2021-04-12T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 7.6,
"platelets_k_uL": 363,
"creatinine_mg_dL": 0.79,
"... |
ANODE_SYNTH_2025_208 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 58,
"sex": "female",
"bmi": 30.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-06-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 17.08
},
"second_line... | {
"overall_survival_months": 31.1,
"censored": false
} | [
{
"date": "2022-04-17T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 8.8,
"platelets_k_uL": 306,
"creatinine_mg_dL": 0.96,
"alt_U_L": 44
},
{
"date": "2022-11-28T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 5,
"platelets_k_uL": 328,
"creatinine_mg_dL": 1.41,
"... |
ANODE_SYNTH_2025_209 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 79,
"sex": "female",
"bmi": 24.4,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.9,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-10-17T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -49
},
"pfs_months": 30.36
},
"second_line... | {
"overall_survival_months": 44.6,
"censored": false
} | [
{
"date": "2020-08-28T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 5.8,
"platelets_k_uL": 252,
"creatinine_mg_dL": 0.72,
"alt_U_L": 38
},
{
"date": "2021-04-15T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 7.9,
"platelets_k_uL": 340,
"creatinine_mg_dL": 0.86,
... |
ANODE_SYNTH_2025_210 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "NTRK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 55,
"sex": "male",
"bmi": 34.4,
"smoking_pack_years": 80,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "larotrectinib 100 mg BID",
"start_date": "2021-11-09T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -43,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 40.94
},
"second_lin... | {
"overall_survival_months": 58,
"censored": true
} | [
{
"date": "2021-10-05T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 10.4,
"platelets_k_uL": 284,
"creatinine_mg_dL": 1.18,
"alt_U_L": 65
},
{
"date": "2022-05-08T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 7.9,
"platelets_k_uL": 278,
"creatinine_mg_dL": 1.54,
... |
ANODE_SYNTH_2025_211 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 53,
"sex": "male",
"bmi": 29.1,
"smoking_pack_years": 53,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"pleura",
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2024-11-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 32.13
},
"second_line_th... | {
"overall_survival_months": 60.3,
"censored": false
} | [
{
"date": "2024-10-19T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 10,
"platelets_k_uL": 356,
"creatinine_mg_dL": 0.85,
"alt_U_L": 76
},
{
"date": "2025-05-06T00:00:00",
"hemoglobin_g_dL": 10.7,
"wbc_k_uL": 6.8,
"platelets_k_uL": 212,
"creatinine_mg_dL": 0.77,
... |
ANODE_SYNTH_2025_212 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 3.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 22
} | {
"age": 49,
"sex": "female",
"bmi": 27.7,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.2,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-11-10T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 25.82
},
"second_line_t... | {
"overall_survival_months": 36.1,
"censored": false
} | [
{
"date": "2021-10-03T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 6.4,
"platelets_k_uL": 258,
"creatinine_mg_dL": 1.3,
"alt_U_L": 65
},
{
"date": "2022-05-09T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 5.4,
"platelets_k_uL": 203,
"creatinine_mg_dL": 1.5,
"... |
ANODE_SYNTH_2025_213 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 72,
"sex": "female",
"bmi": 28.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.7,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-01-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -58
},
"pfs_months": 12.98
},
"second_line... | {
"overall_survival_months": 32.9,
"censored": true
} | [
{
"date": "2021-11-24T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 8.9,
"platelets_k_uL": 253,
"creatinine_mg_dL": 1.07,
"alt_U_L": 43
},
{
"date": "2022-07-11T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.2,
"platelets_k_uL": 295,
"creatinine_mg_dL": 0.79,
... |
ANODE_SYNTH_2025_214 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 25
} | {
"age": 64,
"sex": "male",
"bmi": 29.9,
"smoking_pack_years": 52,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 8,
"metastatic_sites": [
"liver",
"contralateral lung",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-07-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 10.84
},
"second_line_... | {
"overall_survival_months": 27.3,
"censored": false
} | [
{
"date": "2020-06-09T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 4.7,
"platelets_k_uL": 163,
"creatinine_mg_dL": 0.7,
"alt_U_L": 28
},
{
"date": "2021-01-09T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 6.2,
"platelets_k_uL": 336,
"creatinine_mg_dL": 0.82,
... |
ANODE_SYNTH_2025_215 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 66,
"sex": "female",
"bmi": 22.8,
"smoking_pack_years": 31,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"bone",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-11-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 12.71
},
"second_line_... | {
"overall_survival_months": 17.1,
"censored": false
} | [
{
"date": "2023-09-27T00:00:00",
"hemoglobin_g_dL": 15.3,
"wbc_k_uL": 4.6,
"platelets_k_uL": 217,
"creatinine_mg_dL": 1.06,
"alt_U_L": 77
},
{
"date": "2024-05-16T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 8.7,
"platelets_k_uL": 282,
"creatinine_mg_dL": 1.31,
... |
ANODE_SYNTH_2025_216 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 49,
"sex": "male",
"bmi": 30.6,
"smoking_pack_years": 13,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"brain",
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-01-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -16,
"peak_response_20wk_change_percent": -76
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 7.6,
"censored": false
} | [
{
"date": "2023-11-09T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 10.1,
"platelets_k_uL": 328,
"creatinine_mg_dL": 1.17,
"alt_U_L": 14
},
{
"date": "2024-07-01T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 6.7,
"platelets_k_uL": 334,
"creatinine_mg_dL": 0.78,
... |
ANODE_SYNTH_2025_217 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 60,
"sex": "female",
"bmi": 25.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.2,
"metastatic_sites": [
"liver",
"bone",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-06-09T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -82
},
"pfs_months": 15.7
},
"second_line_... | {
"overall_survival_months": 34.6,
"censored": false
} | [
{
"date": "2025-04-16T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 10.4,
"platelets_k_uL": 390,
"creatinine_mg_dL": 0.74,
"alt_U_L": 75
},
{
"date": "2025-12-06T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 4.2,
"platelets_k_uL": 368,
"creatinine_mg_dL": 0.78,
... |
ANODE_SYNTH_2025_218 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 12
} | {
"age": 86,
"sex": "female",
"bmi": 31.3,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-04-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -76
},
"pfs_months": 27.24
},
"second_line... | {
"overall_survival_months": 41.1,
"censored": false
} | [
{
"date": "2020-04-06T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 5.2,
"platelets_k_uL": 302,
"creatinine_mg_dL": 0.72,
"alt_U_L": 22
},
{
"date": "2020-10-22T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 5.5,
"platelets_k_uL": 208,
"creatinine_mg_dL": 0.82,
... |
ANODE_SYNTH_2025_219 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 58,
"sex": "female",
"bmi": 25,
"smoking_pack_years": 51,
"ecog_performance_status": 2,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.2,
"metastatic_sites": [
"bone",
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-01-01T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -57,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 9.56
},
"second_line_t... | {
"overall_survival_months": 19.2,
"censored": true
} | [
{
"date": "2020-12-01T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 7.5,
"platelets_k_uL": 230,
"creatinine_mg_dL": 1.27,
"alt_U_L": 66
},
{
"date": "2021-06-30T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 8.3,
"platelets_k_uL": 271,
"creatinine_mg_dL": 0.98,
... |
ANODE_SYNTH_2025_220 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 25
} | {
"age": 81,
"sex": "female",
"bmi": 28.2,
"smoking_pack_years": 10,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 7.8,
"metastatic_sites": [
"pleura",
"contralateral lung",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-01-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 22.01
... | {
"overall_survival_months": 36.3,
"censored": false
} | [
{
"date": "2024-12-27T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 5.8,
"platelets_k_uL": 416,
"creatinine_mg_dL": 0.95,
"alt_U_L": 48
},
{
"date": "2025-07-22T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 5.3,
"platelets_k_uL": 175,
"creatinine_mg_dL": 0.89,
... |
ANODE_SYNTH_2025_221 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 74,
"sex": "female",
"bmi": 21.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-02-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -27,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 20.27
},
"second_line... | {
"overall_survival_months": 27.7,
"censored": false
} | [
{
"date": "2024-01-28T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 7.7,
"platelets_k_uL": 331,
"creatinine_mg_dL": 0.62,
"alt_U_L": 14
},
{
"date": "2024-08-25T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 8.7,
"platelets_k_uL": 337,
"creatinine_mg_dL": 1.27,
... |
ANODE_SYNTH_2025_222 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 48,
"sex": "female",
"bmi": 28.5,
"smoking_pack_years": 59,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"brain",
"bone",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-06-08T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 6.64
},
"second_line_t... | {
"overall_survival_months": 15.8,
"censored": false
} | [
{
"date": "2023-04-20T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 7,
"platelets_k_uL": 412,
"creatinine_mg_dL": 0.8,
"alt_U_L": 70
},
{
"date": "2023-12-05T00:00:00",
"hemoglobin_g_dL": 10.1,
"wbc_k_uL": 4.7,
"platelets_k_uL": 140,
"creatinine_mg_dL": 1.39,
"a... |
ANODE_SYNTH_2025_223 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 28
} | {
"age": 80,
"sex": "female",
"bmi": 20.8,
"smoking_pack_years": 75,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5,
"metastatic_sites": [
"brain",
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-06-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 18.4
}... | {
"overall_survival_months": 36,
"censored": false
} | [
{
"date": "2022-05-25T00:00:00",
"hemoglobin_g_dL": 12.2,
"wbc_k_uL": 6.2,
"platelets_k_uL": 195,
"creatinine_mg_dL": 1.28,
"alt_U_L": 37
},
{
"date": "2022-12-20T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 7.4,
"platelets_k_uL": 291,
"creatinine_mg_dL": 0.84,
... |
ANODE_SYNTH_2025_224 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 77,
"sex": "female",
"bmi": 19.2,
"smoking_pack_years": 68,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7.3,
"metastatic_sites": [
"pleura",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-02-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 21.88
... | {
"overall_survival_months": 35.1,
"censored": false
} | [
{
"date": "2021-01-23T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 11,
"platelets_k_uL": 436,
"creatinine_mg_dL": 0.93,
"alt_U_L": 10
},
{
"date": "2021-08-05T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 3.9,
"platelets_k_uL": 364,
"creatinine_mg_dL": 1.38,
... |
ANODE_SYNTH_2025_225 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 71,
"sex": "male",
"bmi": 19.2,
"smoking_pack_years": 24,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-02-11T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 35.98
},
"second_line_th... | {
"overall_survival_months": 62.1,
"censored": true
} | [
{
"date": "2025-01-20T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 7.6,
"platelets_k_uL": 415,
"creatinine_mg_dL": 1.2,
"alt_U_L": 80
},
{
"date": "2025-08-10T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 6.6,
"platelets_k_uL": 127,
"creatinine_mg_dL": 1.14,
... |
ANODE_SYNTH_2025_226 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 33
} | {
"age": 75,
"sex": "female",
"bmi": 23.1,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-07-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 14.78
},
"second_line... | {
"overall_survival_months": 18.8,
"censored": false
} | [
{
"date": "2024-07-13T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 6.2,
"platelets_k_uL": 319,
"creatinine_mg_dL": 0.91,
"alt_U_L": 33
},
{
"date": "2025-01-27T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 8.2,
"platelets_k_uL": 253,
"creatinine_mg_dL": 1.42,
... |
ANODE_SYNTH_2025_227 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 88,
"sex": "female",
"bmi": 36.8,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-09-21T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -35
},
"pfs_months": 5.52
},
"second_line_... | {
"overall_survival_months": 20.6,
"censored": false
} | [
{
"date": "2020-07-15T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 6.9,
"platelets_k_uL": 332,
"creatinine_mg_dL": 0.8,
"alt_U_L": 14
},
{
"date": "2021-03-20T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 5.8,
"platelets_k_uL": 289,
"creatinine_mg_dL": 1.03,
... |
ANODE_SYNTH_2025_228 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 24
} | {
"age": 80,
"sex": "female",
"bmi": 20.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"bone",
"pleura",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-05-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -13,
"peak_response_20wk_change_percent": -68
},
"pfs_months": 35.19
},
"second_line... | {
"overall_survival_months": 42,
"censored": true
} | [
{
"date": "2021-03-24T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 7.7,
"platelets_k_uL": 300,
"creatinine_mg_dL": 1.28,
"alt_U_L": 23
},
{
"date": "2021-10-31T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 8.3,
"platelets_k_uL": 237,
"creatinine_mg_dL": 1.36,
... |
ANODE_SYNTH_2025_229 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 2.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 87,
"sex": "female",
"bmi": 35.1,
"smoking_pack_years": 38,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"liver",
"bone",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-01-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -13,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 8.25
},
"second_line_t... | {
"overall_survival_months": 14.9,
"censored": false
} | [
{
"date": "2020-11-27T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 6.3,
"platelets_k_uL": 371,
"creatinine_mg_dL": 0.9,
"alt_U_L": 26
},
{
"date": "2021-07-29T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 8,
"platelets_k_uL": 210,
"creatinine_mg_dL": 0.83,
"alt... |
ANODE_SYNTH_2025_230 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 59,
"sex": "female",
"bmi": 24.7,
"smoking_pack_years": 31,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.6,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-03-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -60
},
"pfs_months": 41.86
},
"second_line_th... | {
"overall_survival_months": 62,
"censored": false
} | [
{
"date": "2023-01-19T00:00:00",
"hemoglobin_g_dL": 14.1,
"wbc_k_uL": 8.2,
"platelets_k_uL": 279,
"creatinine_mg_dL": 0.8,
"alt_U_L": 23
},
{
"date": "2023-09-22T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 3.9,
"platelets_k_uL": 307,
"creatinine_mg_dL": 1.25,
... |
ANODE_SYNTH_2025_231 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 73,
"sex": "female",
"bmi": 19.6,
"smoking_pack_years": 20,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.4,
"metastatic_sites": [
"liver",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2025-12-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 44.48
},
"second_line_th... | {
"overall_survival_months": 65.9,
"censored": false
} | [
{
"date": "2025-11-02T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 5,
"platelets_k_uL": 389,
"creatinine_mg_dL": 1.1,
"alt_U_L": 55
},
{
"date": "2026-06-01T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 6.5,
"platelets_k_uL": 357,
"creatinine_mg_dL": 0.93,
"alt... |
ANODE_SYNTH_2025_232 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 51,
"sex": "male",
"bmi": 25.9,
"smoking_pack_years": 52,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"liver",
"bone",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-05-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -60,
"peak_response_20wk_change_percent": -65
},
"pfs_months": 36.6
},
"second_line_the... | {
"overall_survival_months": 64.5,
"censored": true
} | [
{
"date": "2020-03-11T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 9.1,
"platelets_k_uL": 258,
"creatinine_mg_dL": 0.74,
"alt_U_L": 31
},
{
"date": "2020-11-03T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 7.9,
"platelets_k_uL": 228,
"creatinine_mg_dL": 1.45,
"... |
ANODE_SYNTH_2025_233 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 82,
"sex": "female",
"bmi": 25.2,
"smoking_pack_years": 25,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6,
"metastatic_sites": [
"pleura",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-07-06T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -60
},
"pfs_months": 24.08
},... | {
"overall_survival_months": 42.7,
"censored": false
} | [
{
"date": "2020-05-10T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 7.2,
"platelets_k_uL": 387,
"creatinine_mg_dL": 1.07,
"alt_U_L": 38
},
{
"date": "2021-01-02T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 4.9,
"platelets_k_uL": 194,
"creatinine_mg_dL": 1.39,
"... |
ANODE_SYNTH_2025_234 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 48,
"sex": "female",
"bmi": 36.6,
"smoking_pack_years": 72,
"ecog_performance_status": 0,
"comorbidities": [
"COPD",
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2022-06-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -30,
"peak_response_20wk_change_percent": -66
},
"pfs_months": 19.06
},
"second_line_... | {
"overall_survival_months": 25.2,
"censored": false
} | [
{
"date": "2022-04-25T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 5.7,
"platelets_k_uL": 415,
"creatinine_mg_dL": 1.27,
"alt_U_L": 30
},
{
"date": "2022-12-07T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 5.3,
"platelets_k_uL": 378,
"creatinine_mg_dL": 1.26,
"... |
ANODE_SYNTH_2025_235 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 70,
"sex": "female",
"bmi": 36.3,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"pleura",
"liver",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2026-01-21T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -66
},
"pfs_months": 23
},
"second_line_ther... | {
"overall_survival_months": 32.9,
"censored": false
} | [
{
"date": "2025-11-13T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 10,
"platelets_k_uL": 394,
"creatinine_mg_dL": 0.63,
"alt_U_L": 75
},
{
"date": "2026-07-20T00:00:00",
"hemoglobin_g_dL": 10,
"wbc_k_uL": 5.9,
"platelets_k_uL": 124,
"creatinine_mg_dL": 1.36,
"alt... |
ANODE_SYNTH_2025_236 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 82,
"sex": "female",
"bmi": 22.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.9,
"metastatic_sites": [
"pleura",
"liver",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-09-26T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 29.77
},
"second_line... | {
"overall_survival_months": 48.5,
"censored": false
} | [
{
"date": "2023-09-04T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 8.3,
"platelets_k_uL": 346,
"creatinine_mg_dL": 0.96,
"alt_U_L": 33
},
{
"date": "2024-03-24T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 3.9,
"platelets_k_uL": 351,
"creatinine_mg_dL": 1.07,
... |
ANODE_SYNTH_2025_237 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 75,
"sex": "female",
"bmi": 22.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-05-29T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -46,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 18.07
},
"second_line... | {
"overall_survival_months": 27,
"censored": true
} | [
{
"date": "2023-04-04T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 9.2,
"platelets_k_uL": 299,
"creatinine_mg_dL": 0.97,
"alt_U_L": 18
},
{
"date": "2023-11-25T00:00:00",
"hemoglobin_g_dL": 10.1,
"wbc_k_uL": 6.9,
"platelets_k_uL": 146,
"creatinine_mg_dL": 0.79,
... |
ANODE_SYNTH_2025_238 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 64,
"sex": "male",
"bmi": 25,
"smoking_pack_years": 55,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.2,
"metastatic_sites": [
"pleura",
"contralateral lung",
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2022-03-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -51,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 42.68
},
"second_line_th... | {
"overall_survival_months": 65.3,
"censored": false
} | [
{
"date": "2022-01-12T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 7.1,
"platelets_k_uL": 431,
"creatinine_mg_dL": 1.17,
"alt_U_L": 13
},
{
"date": "2022-09-15T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 8.1,
"platelets_k_uL": 161,
"creatinine_mg_dL": 1.42,
... |
ANODE_SYNTH_2025_239 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 16,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 59,
"sex": "female",
"bmi": 30,
"smoking_pack_years": 16,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 8.3,
"metastatic_sites": [
"contralateral lung",
"bone",
"liver"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-10-02T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -31,
"peak_response_20wk_change_percent": -81
},
"pfs_months": 18.79
},... | {
"overall_survival_months": 27.5,
"censored": false
} | [
{
"date": "2020-09-16T00:00:00",
"hemoglobin_g_dL": 11.6,
"wbc_k_uL": 8.8,
"platelets_k_uL": 363,
"creatinine_mg_dL": 1.18,
"alt_U_L": 17
},
{
"date": "2021-03-31T00:00:00",
"hemoglobin_g_dL": 10.7,
"wbc_k_uL": 6.3,
"platelets_k_uL": 288,
"creatinine_mg_dL": 0.98,
... |
ANODE_SYNTH_2025_240 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 52,
"sex": "male",
"bmi": 30.3,
"smoking_pack_years": 12,
"ecog_performance_status": 1,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 5.8,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-12-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 16.13
... | {
"overall_survival_months": 35.6,
"censored": false
} | [
{
"date": "2021-12-04T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 8.3,
"platelets_k_uL": 447,
"creatinine_mg_dL": 0.84,
"alt_U_L": 75
},
{
"date": "2022-06-28T00:00:00",
"hemoglobin_g_dL": 11.4,
"wbc_k_uL": 6.3,
"platelets_k_uL": 262,
"creatinine_mg_dL": 0.72,
... |
ANODE_SYNTH_2025_241 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 12
} | {
"age": 83,
"sex": "female",
"bmi": 25.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-11-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -28,
"peak_response_20wk_change_percent": -67
},
"pfs_months": 20.47
},
"second_line... | {
"overall_survival_months": 26,
"censored": true
} | [
{
"date": "2021-10-04T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 8,
"platelets_k_uL": 445,
"creatinine_mg_dL": 0.84,
"alt_U_L": 52
},
{
"date": "2022-05-21T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 6.5,
"platelets_k_uL": 131,
"creatinine_mg_dL": 1.17,
"... |
ANODE_SYNTH_2025_242 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 84,
"sex": "male",
"bmi": 28.5,
"smoking_pack_years": 24,
"ecog_performance_status": 2,
"comorbidities": [
"diabetes",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.3,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-12-08T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -35
},
"pfs_months": 11.99
},... | {
"overall_survival_months": 21,
"censored": true
} | [
{
"date": "2022-10-26T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 10.4,
"platelets_k_uL": 315,
"creatinine_mg_dL": 0.91,
"alt_U_L": 26
},
{
"date": "2023-06-06T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 8.5,
"platelets_k_uL": 257,
"creatinine_mg_dL": 1.1,
"... |
ANODE_SYNTH_2025_243 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2
} | {
"age": 63,
"sex": "female",
"bmi": 37.8,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"liver",
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-08-21T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 23.62
},
"second_line... | {
"overall_survival_months": 29.1,
"censored": true
} | [
{
"date": "2022-08-05T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 5.3,
"platelets_k_uL": 352,
"creatinine_mg_dL": 1.14,
"alt_U_L": 64
},
{
"date": "2023-02-17T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 3.9,
"platelets_k_uL": 317,
"creatinine_mg_dL": 0.79,
... |
ANODE_SYNTH_2025_244 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 48,
"sex": "female",
"bmi": 35.5,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.7,
"metastatic_sites": [
"pleura",
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-05-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 25
},
"second_line_th... | {
"overall_survival_months": 28.9,
"censored": false
} | [
{
"date": "2024-04-07T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 5.1,
"platelets_k_uL": 270,
"creatinine_mg_dL": 0.94,
"alt_U_L": 10
},
{
"date": "2024-11-16T00:00:00",
"hemoglobin_g_dL": 10.8,
"wbc_k_uL": 6,
"platelets_k_uL": 249,
"creatinine_mg_dL": 0.73,
"... |
ANODE_SYNTH_2025_245 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 2.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 87,
"sex": "female",
"bmi": 26.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-01-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -54,
"peak_response_20wk_change_percent": -56
},
"pfs_months": 22.51
},
"second_line... | {
"overall_survival_months": 40,
"censored": false
} | [
{
"date": "2024-12-23T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 8.1,
"platelets_k_uL": 391,
"creatinine_mg_dL": 0.83,
"alt_U_L": 33
},
{
"date": "2025-07-26T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 7.1,
"platelets_k_uL": 195,
"creatinine_mg_dL": 0.73,
... |
ANODE_SYNTH_2025_246 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 15
} | {
"age": 77,
"sex": "female",
"bmi": 23.4,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.9,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-08-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 26.84
},
"second_line... | {
"overall_survival_months": 38.5,
"censored": false
} | [
{
"date": "2020-07-03T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 7.6,
"platelets_k_uL": 246,
"creatinine_mg_dL": 0.85,
"alt_U_L": 71
},
{
"date": "2021-02-06T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 4.9,
"platelets_k_uL": 213,
"creatinine_mg_dL": 0.75,
"... |
ANODE_SYNTH_2025_247 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 86,
"sex": "female",
"bmi": 31.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2026-03-03T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 20.73
},
"second_line... | {
"overall_survival_months": 29.3,
"censored": false
} | [
{
"date": "2025-12-28T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 7.1,
"platelets_k_uL": 365,
"creatinine_mg_dL": 0.78,
"alt_U_L": 24
},
{
"date": "2026-08-30T00:00:00",
"hemoglobin_g_dL": 10.2,
"wbc_k_uL": 8.3,
"platelets_k_uL": 201,
"creatinine_mg_dL": 1.14,
... |
ANODE_SYNTH_2025_248 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 11.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 2
} | {
"age": 60,
"sex": "female",
"bmi": 21.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-06-13T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -78
},
"pfs_months": 20.63
},
"second_line_t... | {
"overall_survival_months": 37.7,
"censored": true
} | [
{
"date": "2024-05-09T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 9.6,
"platelets_k_uL": 249,
"creatinine_mg_dL": 1.02,
"alt_U_L": 72
},
{
"date": "2024-12-10T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 5.7,
"platelets_k_uL": 215,
"creatinine_mg_dL": 1.52,
... |
ANODE_SYNTH_2025_249 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 74,
"sex": "male",
"bmi": 31.1,
"smoking_pack_years": 25,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 7.7,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-04-17T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 27.04
},... | {
"overall_survival_months": 42.3,
"censored": true
} | [
{
"date": "2024-02-16T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 4.8,
"platelets_k_uL": 422,
"creatinine_mg_dL": 0.6,
"alt_U_L": 27
},
{
"date": "2024-10-14T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 8.6,
"platelets_k_uL": 179,
"creatinine_mg_dL": 1.32,
... |
ANODE_SYNTH_2025_250 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 60,
"sex": "female",
"bmi": 34.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"brain",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-06-05T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -10,
"peak_response_20wk_change_percent": -66
},
"pfs_months": 16.99
},
"second_line_t... | {
"overall_survival_months": 27.8,
"censored": false
} | [
{
"date": "2020-05-18T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 8.4,
"platelets_k_uL": 341,
"creatinine_mg_dL": 0.73,
"alt_U_L": 24
},
{
"date": "2020-12-02T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 8.4,
"platelets_k_uL": 288,
"creatinine_mg_dL": 1.14,
... |
ANODE_SYNTH_2025_251 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 65,
"sex": "male",
"bmi": 20.8,
"smoking_pack_years": 59,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 4.9,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-10-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 9.33
},
"second_line_t... | {
"overall_survival_months": 18.2,
"censored": false
} | [
{
"date": "2020-09-07T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 9.2,
"platelets_k_uL": 438,
"creatinine_mg_dL": 0.82,
"alt_U_L": 14
},
{
"date": "2021-04-12T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 8.8,
"platelets_k_uL": 249,
"creatinine_mg_dL": 0.78,
... |
ANODE_SYNTH_2025_252 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 6.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 85,
"sex": "female",
"bmi": 21.7,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.4,
"metastatic_sites": [
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-12-31T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 25.2
},
"second_line_th... | {
"overall_survival_months": 38.1,
"censored": false
} | [
{
"date": "2023-11-18T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 10.2,
"platelets_k_uL": 176,
"creatinine_mg_dL": 1.02,
"alt_U_L": 78
},
{
"date": "2024-06-28T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 8,
"platelets_k_uL": 175,
"creatinine_mg_dL": 1.43,
... |
ANODE_SYNTH_2025_253 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 85,
"sex": "male",
"bmi": 24.7,
"smoking_pack_years": 39,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.4,
"metastatic_sites": [
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2022-05-04T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -31,
"peak_response_20wk_change_percent": -66
},
"pfs_months": 16.66
},... | {
"overall_survival_months": 33.2,
"censored": false
} | [
{
"date": "2022-04-06T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 10.8,
"platelets_k_uL": 223,
"creatinine_mg_dL": 1.09,
"alt_U_L": 29
},
{
"date": "2022-10-31T00:00:00",
"hemoglobin_g_dL": 11.3,
"wbc_k_uL": 7.9,
"platelets_k_uL": 151,
"creatinine_mg_dL": 1.09,
... |
ANODE_SYNTH_2025_254 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 53,
"sex": "female",
"bmi": 25.8,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"bone",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-11-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -22,
"peak_response_20wk_change_percent": -80
},
"pfs_months": 26.74
},
"second_line... | {
"overall_survival_months": 38.5,
"censored": false
} | [
{
"date": "2020-10-25T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 9.8,
"platelets_k_uL": 169,
"creatinine_mg_dL": 0.87,
"alt_U_L": 53
},
{
"date": "2021-05-26T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 8.4,
"platelets_k_uL": 269,
"creatinine_mg_dL": 0.88,
... |
ANODE_SYNTH_2025_255 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 71,
"sex": "female",
"bmi": 37.9,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 8.5,
"metastatic_sites": [
"brain",
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-08-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -42,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 17.94
},
"second_line... | {
"overall_survival_months": 32.4,
"censored": false
} | [
{
"date": "2025-07-19T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 7.8,
"platelets_k_uL": 241,
"creatinine_mg_dL": 1.08,
"alt_U_L": 19
},
{
"date": "2026-02-18T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4.6,
"platelets_k_uL": 135,
"creatinine_mg_dL": 1.46,
"... |
ANODE_SYNTH_2025_256 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 35
} | {
"age": 73,
"sex": "male",
"bmi": 28.4,
"smoking_pack_years": 65,
"ecog_performance_status": 0,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2021-05-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -21,
"peak_response_20wk_change_percent": -36
},
"pfs_months": 43.01
},
"second_line_th... | {
"overall_survival_months": 75,
"censored": false
} | [
{
"date": "2021-04-22T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 10.2,
"platelets_k_uL": 434,
"creatinine_mg_dL": 1.07,
"alt_U_L": 30
},
{
"date": "2021-11-06T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 5.8,
"platelets_k_uL": 279,
"creatinine_mg_dL": 0.74,
... |
ANODE_SYNTH_2025_257 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 7.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 17
} | {
"age": 60,
"sex": "female",
"bmi": 26.7,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"COPD",
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-04-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -26,
"peak_response_20wk_change_percent": -42
},
"pfs_months": 27.56
},
"second_line... | {
"overall_survival_months": 41.9,
"censored": false
} | [
{
"date": "2020-03-09T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 5.2,
"platelets_k_uL": 186,
"creatinine_mg_dL": 0.66,
"alt_U_L": 48
},
{
"date": "2020-10-09T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8.4,
"platelets_k_uL": 255,
"creatinine_mg_dL": 0.73,
... |
ANODE_SYNTH_2025_258 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 52,
"sex": "female",
"bmi": 29.4,
"smoking_pack_years": 63,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-11-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -37
},
"pfs_months": 2.96
},
"second_line_t... | {
"overall_survival_months": 15.4,
"censored": false
} | [
{
"date": "2021-09-20T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 7.5,
"platelets_k_uL": 416,
"creatinine_mg_dL": 1.04,
"alt_U_L": 48
},
{
"date": "2022-05-01T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 7.3,
"platelets_k_uL": 134,
"creatinine_mg_dL": 1.22,
... |
ANODE_SYNTH_2025_259 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 9.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 62,
"sex": "female",
"bmi": 37.9,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 8.1,
"metastatic_sites": [
"liver",
"contralateral lung",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-09-30T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -55,
"peak_response_20wk_change_percent": -73
},
"pfs_months": 37.82
},
"second_line... | {
"overall_survival_months": 41.8,
"censored": false
} | [
{
"date": "2024-09-16T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 10.4,
"platelets_k_uL": 329,
"creatinine_mg_dL": 1.22,
"alt_U_L": 75
},
{
"date": "2025-03-29T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 4.3,
"platelets_k_uL": 322,
"creatinine_mg_dL": 1.13,
... |
ANODE_SYNTH_2025_260 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 60,
"sex": "male",
"bmi": 37.1,
"smoking_pack_years": 23,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 3.4,
"metastatic_sites": [
"contralateral lung",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-05-16T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -12,
"peak_response_20wk_change_percent": -47
},
"pfs_months": 45.37
},
"second_line_ther... | {
"overall_survival_months": 72,
"censored": false
} | [
{
"date": "2023-03-12T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 9.3,
"platelets_k_uL": 434,
"creatinine_mg_dL": 0.89,
"alt_U_L": 68
},
{
"date": "2023-11-12T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 5.1,
"platelets_k_uL": 302,
"creatinine_mg_dL": 1.02,
... |
ANODE_SYNTH_2025_261 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 68,
"sex": "male",
"bmi": 22.9,
"smoking_pack_years": 70,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.8,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2021-01-22T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -23,
"peak_response_20wk_change_percent": -33
},
"pfs_months": 17.97
},
"second_line_... | {
"overall_survival_months": 38.5,
"censored": true
} | [
{
"date": "2020-12-03T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 9.6,
"platelets_k_uL": 338,
"creatinine_mg_dL": 1.29,
"alt_U_L": 33
},
{
"date": "2021-07-21T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 8.7,
"platelets_k_uL": 294,
"creatinine_mg_dL": 1.02,
... |
ANODE_SYNTH_2025_262 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 54,
"sex": "female",
"bmi": 33.1,
"smoking_pack_years": 11,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"hypertension"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-12-12T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -14,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 41.17
},
"second_line_th... | {
"overall_survival_months": 68.7,
"censored": true
} | [
{
"date": "2023-11-05T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 5.1,
"platelets_k_uL": 444,
"creatinine_mg_dL": 0.8,
"alt_U_L": 76
},
{
"date": "2024-06-09T00:00:00",
"hemoglobin_g_dL": 13.4,
"wbc_k_uL": 4,
"platelets_k_uL": 296,
"creatinine_mg_dL": 1.4,
"al... |
ANODE_SYNTH_2025_263 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 5.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 8
} | {
"age": 86,
"sex": "female",
"bmi": 21.6,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-03-07T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -35,
"peak_response_20wk_change_percent": -71
},
"pfs_months": 25.66
},
"second_line... | {
"overall_survival_months": 42.9,
"censored": false
} | [
{
"date": "2022-01-02T00:00:00",
"hemoglobin_g_dL": 15.2,
"wbc_k_uL": 7,
"platelets_k_uL": 207,
"creatinine_mg_dL": 0.8,
"alt_U_L": 52
},
{
"date": "2022-09-03T00:00:00",
"hemoglobin_g_dL": 10.7,
"wbc_k_uL": 5.8,
"platelets_k_uL": 317,
"creatinine_mg_dL": 1.24,
"a... |
ANODE_SYNTH_2025_264 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.9,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 12
} | {
"age": 52,
"sex": "female",
"bmi": 33.2,
"smoking_pack_years": 13,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"pleura",
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-04-21T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -11,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 9.89
},
"second_line_the... | {
"overall_survival_months": 26.3,
"censored": true
} | [
{
"date": "2020-03-23T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 5.6,
"platelets_k_uL": 189,
"creatinine_mg_dL": 0.98,
"alt_U_L": 66
},
{
"date": "2020-10-18T00:00:00",
"hemoglobin_g_dL": 10.6,
"wbc_k_uL": 6.6,
"platelets_k_uL": 238,
"creatinine_mg_dL": 0.93,
... |
ANODE_SYNTH_2025_265 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 13
} | {
"age": 50,
"sex": "female",
"bmi": 32.4,
"smoking_pack_years": 35,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"bone",
"liver",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-01-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -46,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 44.42
},
"second_line_th... | {
"overall_survival_months": 77.4,
"censored": true
} | [
{
"date": "2020-01-03T00:00:00",
"hemoglobin_g_dL": 14.2,
"wbc_k_uL": 7.6,
"platelets_k_uL": 413,
"creatinine_mg_dL": 1.3,
"alt_U_L": 41
},
{
"date": "2020-07-16T00:00:00",
"hemoglobin_g_dL": 13.5,
"wbc_k_uL": 8.2,
"platelets_k_uL": 287,
"creatinine_mg_dL": 1.11,
... |
ANODE_SYNTH_2025_266 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 5
} | {
"age": 77,
"sex": "female",
"bmi": 30,
"smoking_pack_years": 23,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.1,
"metastatic_sites": [
"pleura",
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2020-11-02T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -14,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 18.92
},
"second_line_... | {
"overall_survival_months": 29.7,
"censored": false
} | [
{
"date": "2020-10-05T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 5.6,
"platelets_k_uL": 202,
"creatinine_mg_dL": 0.81,
"alt_U_L": 20
},
{
"date": "2021-05-01T00:00:00",
"hemoglobin_g_dL": 10.9,
"wbc_k_uL": 8,
"platelets_k_uL": 313,
"creatinine_mg_dL": 1.17,
"... |
ANODE_SYNTH_2025_267 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 17.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 51,
"sex": "male",
"bmi": 25.9,
"smoking_pack_years": 10,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.7,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-08-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -25,
"peak_response_20wk_change_percent": -48
},
"pfs_months": 20.21
... | {
"overall_survival_months": 30.1,
"censored": false
} | [
{
"date": "2020-07-22T00:00:00",
"hemoglobin_g_dL": 13.9,
"wbc_k_uL": 9.8,
"platelets_k_uL": 350,
"creatinine_mg_dL": 0.74,
"alt_U_L": 49
},
{
"date": "2021-02-12T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 4.6,
"platelets_k_uL": 300,
"creatinine_mg_dL": 0.86,
... |
ANODE_SYNTH_2025_268 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 64,
"sex": "male",
"bmi": 31.7,
"smoking_pack_years": 46,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 6.2,
"metastatic_sites": [
"bone",
"contralateral lung",
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2024-02-11T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -27,
"peak_response_20wk_change_percent": -69
},
"pfs_months": 23.52
... | {
"overall_survival_months": 37.8,
"censored": false
} | [
{
"date": "2024-01-25T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 10.2,
"platelets_k_uL": 400,
"creatinine_mg_dL": 0.66,
"alt_U_L": 67
},
{
"date": "2024-08-09T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 5.6,
"platelets_k_uL": 187,
"creatinine_mg_dL": 1.16,
... |
ANODE_SYNTH_2025_269 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 0
} | {
"age": 77,
"sex": "female",
"bmi": 20.6,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"bone",
"brain",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-03-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -24,
"peak_response_20wk_change_percent": -52
},
"pfs_months": 10.91
},
"second_line... | {
"overall_survival_months": 30.7,
"censored": false
} | [
{
"date": "2023-01-26T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 7.1,
"platelets_k_uL": 405,
"creatinine_mg_dL": 1.06,
"alt_U_L": 41
},
{
"date": "2023-09-02T00:00:00",
"hemoglobin_g_dL": 12.9,
"wbc_k_uL": 7.6,
"platelets_k_uL": 330,
"creatinine_mg_dL": 0.98,
... |
ANODE_SYNTH_2025_270 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 11.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 77,
"sex": "male",
"bmi": 35.6,
"smoking_pack_years": 48,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 5.7,
"metastatic_sites": [
"bone",
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-05-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -30
},
"pfs_months": 18.76
},
"second_line_... | {
"overall_survival_months": 25.6,
"censored": false
} | [
{
"date": "2024-04-12T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8.8,
"platelets_k_uL": 331,
"creatinine_mg_dL": 1.28,
"alt_U_L": 71
},
{
"date": "2024-11-21T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 5.2,
"platelets_k_uL": 194,
"creatinine_mg_dL": 1.08,
... |
ANODE_SYNTH_2025_271 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 8.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 30
} | {
"age": 67,
"sex": "female",
"bmi": 27.8,
"smoking_pack_years": 0,
"ecog_performance_status": 2,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-02-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -62
},
"pfs_months": 25.86
},
"second_line... | {
"overall_survival_months": 45.1,
"censored": false
} | [
{
"date": "2021-01-13T00:00:00",
"hemoglobin_g_dL": 11.7,
"wbc_k_uL": 10.7,
"platelets_k_uL": 289,
"creatinine_mg_dL": 0.75,
"alt_U_L": 80
},
{
"date": "2021-08-18T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4.6,
"platelets_k_uL": 278,
"creatinine_mg_dL": 1.09,
... |
ANODE_SYNTH_2025_272 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 29
} | {
"age": 86,
"sex": "female",
"bmi": 37.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-08-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -26,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 26.32
},
"second_line... | {
"overall_survival_months": 33.3,
"censored": true
} | [
{
"date": "2024-06-25T00:00:00",
"hemoglobin_g_dL": 15.5,
"wbc_k_uL": 6.8,
"platelets_k_uL": 329,
"creatinine_mg_dL": 0.97,
"alt_U_L": 51
},
{
"date": "2025-02-16T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 5.4,
"platelets_k_uL": 276,
"creatinine_mg_dL": 0.88,
... |
ANODE_SYNTH_2025_273 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 10.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 7
} | {
"age": 76,
"sex": "male",
"bmi": 26.2,
"smoking_pack_years": 60,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 7.4,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-09-14T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 12.45
},
"second_line_... | {
"overall_survival_months": 24.5,
"censored": false
} | [
{
"date": "2023-08-14T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 10.8,
"platelets_k_uL": 361,
"creatinine_mg_dL": 0.81,
"alt_U_L": 11
},
{
"date": "2024-03-12T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 7.8,
"platelets_k_uL": 305,
"creatinine_mg_dL": 1,
"al... |
ANODE_SYNTH_2025_274 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 23
} | {
"age": 71,
"sex": "male",
"bmi": 37.2,
"smoking_pack_years": 40,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4,
"metastatic_sites": [
"pleura",
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2021-04-11T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 34.6
},
"second_line_thera... | {
"overall_survival_months": 56.3,
"censored": false
} | [
{
"date": "2021-02-10T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 5.4,
"platelets_k_uL": 229,
"creatinine_mg_dL": 1.3,
"alt_U_L": 34
},
{
"date": "2021-10-08T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 7.8,
"platelets_k_uL": 357,
"creatinine_mg_dL": 1.55,
"a... |
ANODE_SYNTH_2025_275 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 72,
"sex": "male",
"bmi": 28.2,
"smoking_pack_years": 72,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 5.1,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-10-24T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -32,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 19.19
... | {
"overall_survival_months": 35,
"censored": false
} | [
{
"date": "2023-09-26T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 9.6,
"platelets_k_uL": 352,
"creatinine_mg_dL": 0.88,
"alt_U_L": 49
},
{
"date": "2024-04-21T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 5.3,
"platelets_k_uL": 305,
"creatinine_mg_dL": 1.24,
... |
ANODE_SYNTH_2025_276 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 13.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 64,
"sex": "female",
"bmi": 29,
"smoking_pack_years": 57,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.5,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2023-07-13T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 13.93
},
"second_line_... | {
"overall_survival_months": 17.9,
"censored": true
} | [
{
"date": "2023-06-15T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 4.8,
"platelets_k_uL": 416,
"creatinine_mg_dL": 0.63,
"alt_U_L": 29
},
{
"date": "2024-01-09T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 6.7,
"platelets_k_uL": 218,
"creatinine_mg_dL": 0.91,
... |
ANODE_SYNTH_2025_277 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 14.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 84,
"sex": "female",
"bmi": 37,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"liver",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-04-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -50,
"peak_response_20wk_change_percent": -83
},
"pfs_months": 33.54
},
"second_line... | {
"overall_survival_months": 37.5,
"censored": false
} | [
{
"date": "2025-03-26T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 9.6,
"platelets_k_uL": 344,
"creatinine_mg_dL": 0.74,
"alt_U_L": 72
},
{
"date": "2025-10-24T00:00:00",
"hemoglobin_g_dL": 13.6,
"wbc_k_uL": 5.5,
"platelets_k_uL": 137,
"creatinine_mg_dL": 1.14,
"... |
ANODE_SYNTH_2025_278 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 7.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 88,
"sex": "male",
"bmi": 24.3,
"smoking_pack_years": 46,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-10-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 17.77
... | {
"overall_survival_months": 36.7,
"censored": true
} | [
{
"date": "2021-10-01T00:00:00",
"hemoglobin_g_dL": 15.1,
"wbc_k_uL": 4.9,
"platelets_k_uL": 270,
"creatinine_mg_dL": 0.75,
"alt_U_L": 61
},
{
"date": "2022-04-21T00:00:00",
"hemoglobin_g_dL": 13.7,
"wbc_k_uL": 4.4,
"platelets_k_uL": 126,
"creatinine_mg_dL": 1.54,
... |
ANODE_SYNTH_2025_279 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 71,
"sex": "female",
"bmi": 37.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 4.5,
"metastatic_sites": [
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2020-08-19T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -53,
"peak_response_20wk_change_percent": -40
},
"pfs_months": 26.32
},
"second_line... | {
"overall_survival_months": 39.5,
"censored": false
} | [
{
"date": "2020-07-26T00:00:00",
"hemoglobin_g_dL": 13,
"wbc_k_uL": 5.1,
"platelets_k_uL": 364,
"creatinine_mg_dL": 1.17,
"alt_U_L": 42
},
{
"date": "2021-02-15T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 7.1,
"platelets_k_uL": 358,
"creatinine_mg_dL": 1.4,
"a... |
ANODE_SYNTH_2025_280 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 8.5,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 31
} | {
"age": 88,
"sex": "male",
"bmi": 23,
"smoking_pack_years": 52,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.8,
"metastatic_sites": [
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-02-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -45,
"peak_response_20wk_change_percent": -31
},
"pfs_months": 22.01
... | {
"overall_survival_months": 38.5,
"censored": true
} | [
{
"date": "2020-11-27T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 8,
"platelets_k_uL": 277,
"creatinine_mg_dL": 0.97,
"alt_U_L": 18
},
{
"date": "2021-08-03T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 8.3,
"platelets_k_uL": 241,
"creatinine_mg_dL": 0.87,
"... |
ANODE_SYNTH_2025_281 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 60,
"sex": "female",
"bmi": 31.8,
"smoking_pack_years": 65,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-05-25T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -32
},
"pfs_months": 22.14
... | {
"overall_survival_months": 37.4,
"censored": false
} | [
{
"date": "2020-04-24T00:00:00",
"hemoglobin_g_dL": 14.4,
"wbc_k_uL": 5.9,
"platelets_k_uL": 321,
"creatinine_mg_dL": 0.65,
"alt_U_L": 36
},
{
"date": "2020-11-21T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 6.5,
"platelets_k_uL": 266,
"creatinine_mg_dL": 1.27,
... |
ANODE_SYNTH_2025_282 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 16
} | {
"age": 81,
"sex": "female",
"bmi": 35.1,
"smoking_pack_years": 70,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"hypertension"
]
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"contralateral lung",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-02-09T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -17,
"peak_response_20wk_change_percent": -55
},
"pfs_months": 13.08
... | {
"overall_survival_months": 36,
"censored": true
} | [
{
"date": "2021-01-12T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 4.6,
"platelets_k_uL": 157,
"creatinine_mg_dL": 1.07,
"alt_U_L": 52
},
{
"date": "2021-08-08T00:00:00",
"hemoglobin_g_dL": 10.3,
"wbc_k_uL": 5.2,
"platelets_k_uL": 233,
"creatinine_mg_dL": 1.32,
... |
ANODE_SYNTH_2025_283 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 21
} | {
"age": 55,
"sex": "female",
"bmi": 22.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 7.2,
"metastatic_sites": [
"pleura",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-08-05T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -49,
"peak_response_20wk_change_percent": -85
},
"pfs_months": 28.85
},
"second_line... | {
"overall_survival_months": 42.7,
"censored": false
} | [
{
"date": "2021-06-06T00:00:00",
"hemoglobin_g_dL": 14.3,
"wbc_k_uL": 8.1,
"platelets_k_uL": 205,
"creatinine_mg_dL": 1.06,
"alt_U_L": 13
},
{
"date": "2022-02-01T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 4.2,
"platelets_k_uL": 373,
"creatinine_mg_dL": 1.5,
... |
ANODE_SYNTH_2025_284 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 4.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 64,
"sex": "female",
"bmi": 34.5,
"smoking_pack_years": 28,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes",
"COPD"
]
} | {
"primary_tumor_size_cm": 4.8,
"metastatic_sites": [
"liver",
"bone",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-01-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -15,
"peak_response_20wk_change_percent": -34
},
"pfs_months": 39.29
},
"second_line_th... | {
"overall_survival_months": 66.9,
"censored": false
} | [
{
"date": "2022-12-04T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 8.4,
"platelets_k_uL": 207,
"creatinine_mg_dL": 1.12,
"alt_U_L": 14
},
{
"date": "2023-07-03T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 8.6,
"platelets_k_uL": 180,
"creatinine_mg_dL": 1.4,
"a... |
ANODE_SYNTH_2025_285 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 61,
"sex": "male",
"bmi": 30.7,
"smoking_pack_years": 72,
"ecog_performance_status": 2,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 7,
"metastatic_sites": [
"contralateral lung",
"bone",
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-09-27T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -33,
"peak_response_20wk_change_percent": -43
},
"pfs_months": 39.13
},
"second_line_th... | {
"overall_survival_months": 62.1,
"censored": false
} | [
{
"date": "2020-08-23T00:00:00",
"hemoglobin_g_dL": 15,
"wbc_k_uL": 10.4,
"platelets_k_uL": 422,
"creatinine_mg_dL": 0.8,
"alt_U_L": 71
},
{
"date": "2021-03-26T00:00:00",
"hemoglobin_g_dL": 12.3,
"wbc_k_uL": 5.6,
"platelets_k_uL": 257,
"creatinine_mg_dL": 1.52,
"... |
ANODE_SYNTH_2025_286 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 79,
"sex": "male",
"bmi": 26.8,
"smoking_pack_years": 49,
"ecog_performance_status": 0,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.5,
"metastatic_sites": [
"brain",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2024-09-10T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -59,
"peak_response_20wk_change_percent": -34
},
"pfs_months": 15.44
},
"second_line_... | {
"overall_survival_months": 25.7,
"censored": false
} | [
{
"date": "2024-07-20T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 7.7,
"platelets_k_uL": 417,
"creatinine_mg_dL": 0.67,
"alt_U_L": 27
},
{
"date": "2025-03-09T00:00:00",
"hemoglobin_g_dL": 11.2,
"wbc_k_uL": 3.9,
"platelets_k_uL": 181,
"creatinine_mg_dL": 1.2,
... |
ANODE_SYNTH_2025_287 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 10.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 14
} | {
"age": 60,
"sex": "female",
"bmi": 33.7,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"COPD"
]
} | {
"primary_tumor_size_cm": 6.6,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-12-16T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -11,
"peak_response_20wk_change_percent": -51
},
"pfs_months": 15.7
},
"second_line_... | {
"overall_survival_months": 40.1,
"censored": true
} | [
{
"date": "2021-11-19T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 5.1,
"platelets_k_uL": 388,
"creatinine_mg_dL": 1.15,
"alt_U_L": 65
},
{
"date": "2022-06-14T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 8.5,
"platelets_k_uL": 363,
"creatinine_mg_dL": 1.2,
... |
ANODE_SYNTH_2025_288 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 75,
"sex": "male",
"bmi": 26.4,
"smoking_pack_years": 57,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.4,
"metastatic_sites": [
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-08-06T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -20,
"peak_response_20wk_change_percent": -75
},
"pfs_months": 27.47
... | {
"overall_survival_months": 42.5,
"censored": false
} | [
{
"date": "2020-07-02T00:00:00",
"hemoglobin_g_dL": 12,
"wbc_k_uL": 9.3,
"platelets_k_uL": 418,
"creatinine_mg_dL": 0.84,
"alt_U_L": 26
},
{
"date": "2021-02-02T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 5.7,
"platelets_k_uL": 264,
"creatinine_mg_dL": 1.57,
"... |
ANODE_SYNTH_2025_289 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 27
} | {
"age": 78,
"sex": "female",
"bmi": 18.9,
"smoking_pack_years": 52,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.8,
"metastatic_sites": [
"pleura"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2023-04-18T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -47,
"peak_response_20wk_change_percent": -70
},
"pfs_months": 41.66
},
"second_line_ther... | {
"overall_survival_months": 69.8,
"censored": false
} | [
{
"date": "2023-02-15T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 6.8,
"platelets_k_uL": 295,
"creatinine_mg_dL": 0.65,
"alt_U_L": 25
},
{
"date": "2023-10-15T00:00:00",
"hemoglobin_g_dL": 12.8,
"wbc_k_uL": 7.3,
"platelets_k_uL": 182,
"creatinine_mg_dL": 1.18,
... |
ANODE_SYNTH_2025_290 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 5.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 49,
"sex": "female",
"bmi": 27.8,
"smoking_pack_years": 42,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension"
]
} | {
"primary_tumor_size_cm": 4.1,
"metastatic_sites": [
"brain",
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2023-08-04T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -48,
"peak_response_20wk_change_percent": -84
},
"pfs_months": 17.71
... | {
"overall_survival_months": 33.6,
"censored": false
} | [
{
"date": "2023-06-09T00:00:00",
"hemoglobin_g_dL": 14.8,
"wbc_k_uL": 8.9,
"platelets_k_uL": 302,
"creatinine_mg_dL": 1.04,
"alt_U_L": 23
},
{
"date": "2024-01-31T00:00:00",
"hemoglobin_g_dL": 10.1,
"wbc_k_uL": 5.1,
"platelets_k_uL": 164,
"creatinine_mg_dL": 0.77,
... |
ANODE_SYNTH_2025_291 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 17.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 4
} | {
"age": 73,
"sex": "female",
"bmi": 31.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 7.7,
"metastatic_sites": [
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2025-12-18T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -44,
"peak_response_20wk_change_percent": -35
},
"pfs_months": 17.84
},
"second_line... | {
"overall_survival_months": 32.6,
"censored": false
} | [
{
"date": "2025-10-22T00:00:00",
"hemoglobin_g_dL": 14.9,
"wbc_k_uL": 9.7,
"platelets_k_uL": 383,
"creatinine_mg_dL": 0.74,
"alt_U_L": 46
},
{
"date": "2026-06-16T00:00:00",
"hemoglobin_g_dL": 13.1,
"wbc_k_uL": 4.1,
"platelets_k_uL": 208,
"creatinine_mg_dL": 1.22,
... |
ANODE_SYNTH_2025_292 | Non-small cell lung cancer | Adenocarcinoma | IVB | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 4.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 9
} | {
"age": 66,
"sex": "female",
"bmi": 26.3,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"hyperlipidemia"
]
} | {
"primary_tumor_size_cm": 6,
"metastatic_sites": [
"bone",
"contralateral lung",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2023-09-06T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -39
},
"pfs_months": 28.94
},
"second_line_t... | {
"overall_survival_months": 44.7,
"censored": true
} | [
{
"date": "2023-08-02T00:00:00",
"hemoglobin_g_dL": 11.8,
"wbc_k_uL": 10.5,
"platelets_k_uL": 229,
"creatinine_mg_dL": 1.29,
"alt_U_L": 79
},
{
"date": "2024-03-04T00:00:00",
"hemoglobin_g_dL": 11,
"wbc_k_uL": 6.9,
"platelets_k_uL": 226,
"creatinine_mg_dL": 1.42,
... |
ANODE_SYNTH_2025_293 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 12.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 18
} | {
"age": 87,
"sex": "female",
"bmi": 33.8,
"smoking_pack_years": 0,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.3,
"metastatic_sites": [
"contralateral lung",
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2022-04-07T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -28,
"peak_response_20wk_change_percent": -68
},
"pfs_months": 24.31
},
"second_line_t... | {
"overall_survival_months": 37.1,
"censored": true
} | [
{
"date": "2022-02-26T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 5.2,
"platelets_k_uL": 261,
"creatinine_mg_dL": 0.98,
"alt_U_L": 25
},
{
"date": "2022-10-04T00:00:00",
"hemoglobin_g_dL": 11.5,
"wbc_k_uL": 7,
"platelets_k_uL": 340,
"creatinine_mg_dL": 1.51,
"... |
ANODE_SYNTH_2025_294 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 6.4,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 83,
"sex": "female",
"bmi": 30,
"smoking_pack_years": 66,
"ecog_performance_status": 0,
"comorbidities": [
"hyperlipidemia",
"COPD"
]
} | {
"primary_tumor_size_cm": 8.4,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2021-10-08T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -41,
"peak_response_20wk_change_percent": -50
},
"pfs_months": 12.85
},... | {
"overall_survival_months": 26.2,
"censored": false
} | [
{
"date": "2021-09-08T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 7.2,
"platelets_k_uL": 180,
"creatinine_mg_dL": 0.7,
"alt_U_L": 34
},
{
"date": "2022-04-06T00:00:00",
"hemoglobin_g_dL": 12.6,
"wbc_k_uL": 5.3,
"platelets_k_uL": 334,
"creatinine_mg_dL": 1.22,
... |
ANODE_SYNTH_2025_295 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR exon 19 deletion",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 15.2,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 34
} | {
"age": 53,
"sex": "female",
"bmi": 21.2,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 6.7,
"metastatic_sites": [
"liver",
"pleura"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2024-05-31T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -37,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 26.84
},
"second_line... | {
"overall_survival_months": 41.9,
"censored": false
} | [
{
"date": "2024-05-11T00:00:00",
"hemoglobin_g_dL": 14.5,
"wbc_k_uL": 8.6,
"platelets_k_uL": 308,
"creatinine_mg_dL": 0.72,
"alt_U_L": 38
},
{
"date": "2024-11-27T00:00:00",
"hemoglobin_g_dL": 12.7,
"wbc_k_uL": 4,
"platelets_k_uL": 233,
"creatinine_mg_dL": 1.38,
"... |
ANODE_SYNTH_2025_296 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 3.8,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 1
} | {
"age": 51,
"sex": "male",
"bmi": 35.2,
"smoking_pack_years": 27,
"ecog_performance_status": 1,
"comorbidities": []
} | {
"primary_tumor_size_cm": 4.2,
"metastatic_sites": [
"brain",
"liver"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2025-06-20T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -57
},
"pfs_months": 22.74
... | {
"overall_survival_months": 41.6,
"censored": false
} | [
{
"date": "2025-04-26T00:00:00",
"hemoglobin_g_dL": 14,
"wbc_k_uL": 10.3,
"platelets_k_uL": 393,
"creatinine_mg_dL": 1.22,
"alt_U_L": 54
},
{
"date": "2025-12-17T00:00:00",
"hemoglobin_g_dL": 11.9,
"wbc_k_uL": 5.9,
"platelets_k_uL": 177,
"creatinine_mg_dL": 0.85,
... |
ANODE_SYNTH_2025_297 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "EGFR L858R",
"t790m_resistance": false,
"tumor_mutational_burden_mut_Mb": 16.3,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 6
} | {
"age": 57,
"sex": "female",
"bmi": 35.5,
"smoking_pack_years": 0,
"ecog_performance_status": 1,
"comorbidities": [
"diabetes"
]
} | {
"primary_tumor_size_cm": 5.2,
"metastatic_sites": [
"bone"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "osimertinib 80 mg daily",
"start_date": "2021-01-23T00:00:00",
"best_response": "Partial response",
"radiologic_response": {
"first_ct_8wk_change_percent": -29,
"peak_response_20wk_change_percent": -59
},
"pfs_months": 22.05
},
"second_line... | {
"overall_survival_months": 33.5,
"censored": false
} | [
{
"date": "2020-12-05T00:00:00",
"hemoglobin_g_dL": 13.8,
"wbc_k_uL": 6.4,
"platelets_k_uL": 297,
"creatinine_mg_dL": 1.08,
"alt_U_L": 52
},
{
"date": "2021-07-22T00:00:00",
"hemoglobin_g_dL": 12.1,
"wbc_k_uL": 4.4,
"platelets_k_uL": 264,
"creatinine_mg_dL": 0.89,
... |
ANODE_SYNTH_2025_298 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "ALK fusion",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 12.6,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 32
} | {
"age": 63,
"sex": "female",
"bmi": 32.6,
"smoking_pack_years": 66,
"ecog_performance_status": 1,
"comorbidities": [
"COPD"
]
} | {
"primary_tumor_size_cm": 4.6,
"metastatic_sites": [
"liver",
"bone",
"contralateral lung"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."
} | {
"first_line_therapy": {
"regimen": "alectinib 600 mg BID",
"start_date": "2020-12-29T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -58,
"peak_response_20wk_change_percent": -79
},
"pfs_months": 44.85
},
"second_line_ther... | {
"overall_survival_months": 69.8,
"censored": false
} | [
{
"date": "2020-10-23T00:00:00",
"hemoglobin_g_dL": 14.6,
"wbc_k_uL": 9.5,
"platelets_k_uL": 302,
"creatinine_mg_dL": 0.71,
"alt_U_L": 11
},
{
"date": "2021-06-27T00:00:00",
"hemoglobin_g_dL": 11.1,
"wbc_k_uL": 5,
"platelets_k_uL": 238,
"creatinine_mg_dL": 1.53,
"... |
ANODE_SYNTH_2025_299 | Non-small cell lung cancer | Adenocarcinoma | IV | {
"driver_mutation": "KRAS G12C",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 9.7,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 10
} | {
"age": 62,
"sex": "female",
"bmi": 32.1,
"smoking_pack_years": 80,
"ecog_performance_status": 0,
"comorbidities": []
} | {
"primary_tumor_size_cm": 3.3,
"metastatic_sites": [
"contralateral lung"
],
"brain_metastases_present": false,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "sotorasib 960 mg daily",
"start_date": "2025-03-21T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -34,
"peak_response_20wk_change_percent": -46
},
"pfs_months": 12.85
},
"second_line_th... | {
"overall_survival_months": 28.9,
"censored": true
} | [
{
"date": "2025-02-26T00:00:00",
"hemoglobin_g_dL": 13.2,
"wbc_k_uL": 5.3,
"platelets_k_uL": 433,
"creatinine_mg_dL": 0.68,
"alt_U_L": 24
},
{
"date": "2025-09-17T00:00:00",
"hemoglobin_g_dL": 12.4,
"wbc_k_uL": 8.5,
"platelets_k_uL": 186,
"creatinine_mg_dL": 0.76,
... |
ANODE_SYNTH_2025_300 | Non-small cell lung cancer | Squamous cell carcinoma | IV | {
"driver_mutation": "None (PD-L1 high)",
"t790m_resistance": null,
"tumor_mutational_burden_mut_Mb": 14.1,
"microsatellite_status": "MSS",
"pd_l1_tps_percent": 20
} | {
"age": 50,
"sex": "male",
"bmi": 22.2,
"smoking_pack_years": 12,
"ecog_performance_status": 1,
"comorbidities": [
"hypertension",
"diabetes"
]
} | {
"primary_tumor_size_cm": 3.6,
"metastatic_sites": [
"pleura",
"liver",
"brain"
],
"brain_metastases_present": true,
"radiology_summary": "PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."
} | {
"first_line_therapy": {
"regimen": "carboplatin + pemetrexed + pembrolizumab",
"start_date": "2020-10-02T00:00:00",
"best_response": "Stable disease",
"radiologic_response": {
"first_ct_8wk_change_percent": -46,
"peak_response_20wk_change_percent": -61
},
"pfs_months": 33.84
},... | {
"overall_survival_months": 43.9,
"censored": false
} | [
{
"date": "2020-08-22T00:00:00",
"hemoglobin_g_dL": 12.5,
"wbc_k_uL": 9.8,
"platelets_k_uL": 412,
"creatinine_mg_dL": 0.86,
"alt_U_L": 22
},
{
"date": "2021-03-31T00:00:00",
"hemoglobin_g_dL": 13.3,
"wbc_k_uL": 4.9,
"platelets_k_uL": 133,
"creatinine_mg_dL": 1.32,
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.